Clinical trial
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With…
NCT00243503 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00243503 |
|---|---|
| Title | Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer |
| Official title | A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | SU011248/Trastuzumab |
| Enrollment | 60 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Jul 1, 2010 |
| First posted | Oct 24, 2005 |
| Last update posted | Jul 22, 2011 |
| Countries | Belgium, Canada, France, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: